JPRN-UMIN000001478已完成未知
A combination of cinacalcet with maxacalcitol for regression of moderate to advanced secondary hyperparathyroidism in patients on chronic hemodialysis - Combined therapy of cinacalcet with maxacalcitol for regression of secondary hyperparathyroidism
Kitano Hospital Division of Nephrology and Dialysis0 个研究点目标入组 50 人开始时间: 2009年10月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Uncontrolled ischemic heart disease, heart failure, and arrhythmia 2) Stroke within 6 months 3) Peripheral artery didease of Fontaine 3 and 4 4) Severe liver cirrhosis 5) Malignancy within 3 years 6) Uncontrolled phychosis 7) Attendant for other clinical studies within 3 months 8) Pregnant woman or man who wish for baby 9) Unsuitable patients
研究者
相似试验
已完成
不适用
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.Hypercalcemia with persistent hyperparathyroidism in renal transplant recipients.JPRN-UMIN000003236St Marianna University15
已完成
不适用
Cinacalcet and concurrent intravenous calcitriol for treatment of secondary hyperparathyroidism in dialysis patients compared with intravenous calcitriol alonesecondary hyperparathyroidismJPRN-UMIN0000034381.Division of Internal medicine, Seseragi hospital 2.Department of Medicine & Biological Science Gunma University Graduate School of Medicine100
已完成
4 期
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatioprimary hyperparathyroidismhyperactive parathyroid glands1008362410033949NL-OMON34871eids Universitair Medisch Centrum20
进行中（未招募）
不适用
Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failureBone's disorders and mineral metabolism and vascular involvementMedDRA version: 16.1Level: PTClassification code 10051753Term: Vascular calcificationSystem Organ Class: 10047065 - Vascular disordersEUCTR2013-002270-52-ESHospital Universitari de Girona Dr.Josep Trueta
进行中（未招募）
不适用
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2010-018861-53-NLeiden University Medical Center